Toggle Summary
|
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion to Conduct a Thorough Analysis of the Unblinded Study Data Before Making a Final Determination Conference Call
|
View HTML
|
Toggle Summary
|
Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
LAWRENCEVILLE, N.J , June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC) is scheduled to meet during the first half of July to conduct the second pre-planned interim safety
|
View HTML
|
Toggle Summary
|
Celsion Corporation Announces Closing of Public Offering of Common Stock
Lawrenceville, NJ , June 24, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering of 2,666,667 shares of common stock, resulting in net proceeds of $9.3 million , after deducting
|
View HTML
|
Toggle Summary
|
Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock
Lawrenceville, NJ , June 22, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to the sale of 2,666,667 shares of its common stock at an offering price of $3.75 per share, less
|
View HTML
|
Toggle Summary
|
Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
Excellent Surgical Response Noted at the Higher, 100 mg/m 2 Dose Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month Period, Up to 17 Doses LAWRENCEVILLE, N.J. , May 29, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:
|
View HTML
|
Toggle Summary
|
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced financial results for the three
|
View HTML
|
Toggle Summary
|
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020
LAWRENCEVILLE, N.J. , May 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first quarter ended March 31, 2020 and provide an update on its development programs for ThermoDox ® , its
|
View HTML
|
Toggle Summary
|
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program
Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events Sale of an Additional $2.0 Million of NOL’s Expected in the 4 th Quarter of 2020 LAWRENCEVILLE, N.J. , April 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology
|
View HTML
|
Toggle Summary
|
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J. , April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that the prescribed minimum number of events of 158
|
View HTML
|
Toggle Summary
|
Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage III/IV Ovarian Cancer LAWRENCEVILLE, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation
|
View HTML
|